Literature DB >> 7889961

Comparative studies of cefprozil in the management of skin and soft-tissue infections.

T Nolen1.   

Abstract

Six multicenter clinical trials comparing cefprozil with cefaclor, amoxicillin-clavulanate or erythromycin in the management of skin and soft-tissue infections caused by susceptible bacteria demonstrate that cefprozil, given once or twice daily, is an effective chemotherapeutic agent in this context. Its pharmacokinetic behavior is compatible with once-daily or twice-daily administration, with a probability of improved patient compliance. Safety and tolerability compare favorably with other agents used in skin and soft-tissue infections.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7889961     DOI： 10.1007/bf02111354

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  7 in total

1.  Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Skin-isolated, community-acquired Staphylococcus aureus: in vitro resistance to methicillin and erythromycin.

Authors:  N Ohana; J Keness; E Verner; R Raz; D Rozenman; F Zuckerman
Journal:  J Am Acad Dermatol       Date:  1989-09       Impact factor: 11.527

3.  In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.

Authors:  M Hiraoka; S Masuyoshi; K Tomatsu; M Inoue; S Mitsuhashi
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

4.  In vitro activity of BMY-28100 against common isolates from pediatric infections.

Authors:  R K Scribner; M I Marks; B D Finkhouse
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  Comparative antibacterial activity of the new oral cephalosporin BMY-28100.

Authors:  F H Kayser
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

6.  Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

7.  Comparative in vitro activity of the new oral cephalosporin BMY-28100.

Authors:  K E Aldridge; D D Schiro; C V Sanders
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267
  7 in total
  3 in total

1.  Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.

Authors:  G A Tarshis; B M Miskin; T M Jones; J Champlin; K J Wingert; J D Breen; M J Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 2.  Staphylococcal skin infections in children: rational drug therapy recommendations.

Authors:  Shamez Ladhani; Mehdi Garbash
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  Comparative evaluation of 2 g single dose versus conventional dose azithromycin in uncomplicated skin and skin structure infections.

Authors:  Sudipta Kumar Dey; Amal Kanti Das; Sumit Sen; Avijit Hazra
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.